I’ve been a lab tech on the stability side for 3 years, running ICH studies (25°C/60%RH and 40°C/75%RH) and HPLC assays on an Agilent 1260, and I’m trying to pivot into formulation work. For those who’ve made that move, what should I emphasize — pre-formulation screening, excipient compatibility, small DoE batches — and is it realistic to cross over without an M.S?
We got the most measurable lift from PRMIA’s KRI & Risk Appetite workshop — it made us rebuild early-warning KRIs and backtest thresholds on 24 months of our own data; noisy alerts dropped and we caught a liquidity buffer drift about two weeks earlier. If you do GARP’s liquidity module, add a small “red team” drill to break your stress assumptions and bake any fixes into your KRI library — less acronym bingo, more thresholds that bite. ISO 31000’s solid for governance, but it won’t move triggers without hands-on backtesting — want a one-pager of the template we used?
It’s realistic without an M.S. — , the gatekeeping is overblown. Pitch to run a tiny preformulation screen: 5–10 g blends with a 2–3 factor DoE on excipient compatibility, pull 1–2 week “40°C/75%RH” and “25°C/60%RH” holds, and read out on the Agilent 1260 to build a portfolio; big pharma may still prefer the degree, but CDMOs are more flexible — framing it in ICH Q8/QbD terms helps: ICH Official web site : ICH. Would your current team let you pilot a couple of those quick screens?